267 related articles for article (PubMed ID: 35628190)
21. Molecular pathogenesis of primary hyperparathyroidism.
Cetani F; Pardi E; Borsari S; Marcocci C
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
[TBL] [Abstract][Full Text] [Related]
22. CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.
Korpi-Hyövälti E; Cranston T; Ryhänen E; Arola J; Aittomäki K; Sane T; Thakker RV; Schalin-Jäntti C
J Clin Endocrinol Metab; 2014 Sep; 99(9):3044-8. PubMed ID: 24823466
[TBL] [Abstract][Full Text] [Related]
23. Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.
Walls GV; Stevenson M; Lines KE; Newey PJ; Reed AAC; Bowl MR; Jeyabalan J; Harding B; Bradley KJ; Manek S; Chen J; Wang P; Williams BO; Teh BT; Thakker RV
Oncogene; 2017 Jul; 36(28):4025-4036. PubMed ID: 28288139
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
[TBL] [Abstract][Full Text] [Related]
25. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
26. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism.
Pannett AA; Kennedy AM; Turner JJ; Forbes SA; Cavaco BM; Bassett JH; Cianferotti L; Harding B; Shine B; Flinter F; Maidment CG; Trembath R; Thakker RV
Clin Endocrinol (Oxf); 2003 May; 58(5):639-46. PubMed ID: 12699448
[TBL] [Abstract][Full Text] [Related]
27. Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism.
Dwight T; Nelson AE; Theodosopoulos G; Richardson AL; Learoyd DL; Philips J; Delbridge L; Zedenius J; Teh BT; Larsson C; Marsh DJ; Robinson BG
Am J Pathol; 2002 Oct; 161(4):1299-306. PubMed ID: 12368203
[TBL] [Abstract][Full Text] [Related]
28. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.
Newey PJ; Bowl MR; Cranston T; Thakker RV
Hum Mutat; 2010 Mar; 31(3):295-307. PubMed ID: 20052758
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism.
Libutti SK; Crabtree JS; Lorang D; Burns AL; Mazzanti C; Hewitt SM; O'Connor S; Ward JM; Emmert-Buck MR; Remaley A; Miller M; Turner E; Alexander HR; Arnold A; Marx SJ; Collins FS; Spiegel AM
Cancer Res; 2003 Nov; 63(22):8022-8. PubMed ID: 14633735
[TBL] [Abstract][Full Text] [Related]
30. Familial isolated hyperparathyroidism caused by single adenoma: a distinct entity different from multiple endocrine neoplasia.
Watanabe T; Tsukamoto F; Shimizu T; Sugimoto T; Taguchi T; Nishisho I; Nakazawa H; Shiba E; Shishiba Y; Takai S
Endocr J; 1998 Oct; 45(5):637-46. PubMed ID: 10395244
[TBL] [Abstract][Full Text] [Related]
31. MEN1 gene alterations do not correlate with the phenotype of sporadic primary hyperparathyroidism.
Cetani F; Pardi E; Vignali E; Borsari S; Picone A; Cianferotti L; Ambrogini E; Miccoli P; Pinchera A; Marcocci C
J Endocrinol Invest; 2002 Jun; 25(6):508-12. PubMed ID: 12109621
[TBL] [Abstract][Full Text] [Related]
32. MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM.
Arnold A
Trans Am Clin Climatol Assoc; 2016; 127():235-244. PubMed ID: 28066056
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic insights into sporadic primary hyperparathyroidism.
Brewer K; Costa-Guda J; Arnold A
Endocr Relat Cancer; 2019 Feb; 26(2):R53-R72. PubMed ID: 30475215
[TBL] [Abstract][Full Text] [Related]
34. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas.
Välimäki S; Forsberg L; Farnebo LO; Larsson C
Int J Oncol; 2002 Oct; 21(4):727-35. PubMed ID: 12239610
[TBL] [Abstract][Full Text] [Related]
35. Genetics of parathyroid tumours.
Thakker RV
J Intern Med; 2016 Dec; 280(6):574-583. PubMed ID: 27306766
[TBL] [Abstract][Full Text] [Related]
36. The EIF4EBP3 translational repressor is a marker of CDC73 tumor suppressor haploinsufficiency in a parathyroid cancer syndrome.
Zhang JH; Seigneur EM; Pandey M; Loshakov A; Dagur PK; Connelly PS; Koo L; Panicker LM; Simonds WF
Cell Death Dis; 2012 Feb; 3(2):266. PubMed ID: 22297294
[TBL] [Abstract][Full Text] [Related]
37. Intratumor heterogeneity in human parathyroid tumors.
Verdelli C; Tavanti GS; Corbetta S
Histol Histopathol; 2020 Nov; 35(11):1213-1228. PubMed ID: 32468569
[TBL] [Abstract][Full Text] [Related]
38. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathology of parathyroid tumors.
Carling T
Trends Endocrinol Metab; 2001 Mar; 12(2):53-8. PubMed ID: 11167122
[TBL] [Abstract][Full Text] [Related]
40. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
